Get the Stockscreener App
1.14
0.88%
0.01
Aclaris Therapeutics Inc stock is traded at $1.14, with a volume of 665.91K.
It is up +0.88% in the last 24 hours and down -27.85% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
See More
Previous Close:
$1.13
Open:
$1.12
24h Volume:
665.91K
Relative Volume:
0.77
Market Cap:
$127.61M
Revenue:
$27.08M
Net Income/Loss:
$-37.00M
P/E Ratio:
-2.1923
EPS:
-0.52
Net Cash Flow:
$-18.46M
1W Performance:
+5.56%
1M Performance:
-27.85%
6M Performance:
-2.56%
1Y Performance:
-7.32%
1-Day Range:
$1.08
$1.15
1-Week Range:
$1.08
$1.23
52-Week Range:
$0.9515
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.14 | 127.61M | 27.08M | -37.00M | -18.46M | -0.52 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com
Arthralgia Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis - The Globe and Mail
Commonwealth Equity Services LLC Buys New Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN
Aclaris Therapeutics Inc (ACRS) Has Recovered 21.49% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
Raymond James Financial Inc. Acquires Shares of 154,351 Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) see US$21m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Charles Schwab Investment Management Inc. Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.67 - Defense World
Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely? - Yahoo Finance
HighTower Advisors LLC Has $652,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris at H.C. Wainwright Conference: Strategic Moves in Immuno-Inflammatory Diseases - Investing.com India
Cantor Fitzgerald Has Weak Forecast for ACRS FY2025 Earnings - The AM Reporter
Aclaris Therapeutics ATM - Leerink Partners
Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald - Yahoo Finance
Aclaris Therapeutics (NASDAQ:ACRS) Now Covered by Analysts at Cantor Fitzgerald - Defense World
Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 - MSN
Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion By Investing.com - Investing.com South Africa
Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion - Investing.com
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MSN
Common Warts Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
Scotiabank Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Scotiabank Initiates Coverage of Aclaris Therapeutics (ACRS) with Sector Outperform Recommendation - Nasdaq
Scotiabank sets Aclaris stock target at $15 with new rating - Investing.com
Scotiabank sets Aclaris stock target at $15 with new rating By Investing.com - Investing.com UK
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St
Cantor Fitzgerald Predicts ACRS FY2025 Earnings - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $11.00 - Defense World
Aclaris Therapeutics (NASDAQ:ACRS shareholders incur further losses as stock declines 12% this week, taking three-year losses to 88% - Simply Wall St
Cantor Fitzgerald Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Strong-Buy - Defense World
Aclaris Therapeutics plans $300M mixed shelf offering - MSN
Aclaris Therapeutics to Participate in Two March Healthcare Conferences - GlobeNewswire
Will Aclaris Therapeutics Reveal New Pipeline Updates at March Healthcare Conferences? - StockTitan
This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Yahoo Finance
JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Aclaris Therapeutics Inc (NASDAQ: ACRS): Hidden Gems In A Time Of Volatility - Stocks Register
Hair Loss Treatment Market Hits New High | Major Giants Follica, Theradome, Histogen, Aclaris Therapeutics - Newstrail
Q1 Earnings Forecast for ACRS Issued By Leerink Partnrs - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results - MarketBeat
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):